Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study.

Andrea ChiricozziNiccolò GoriAlessandra NarcisiAnna BalatoAlessio GambardellaMichela OrtoncelliAngelo Valerio MarzanoRiccardo BalestriGiovanni PalazzoMichele PellegrinoMarco RomanelliGiovanni TripepiKetty PerisAntonio Costanzonull null

Published in: Drugs in R&D (2022)

Elevated effectiveness and favorable safety of upadacitinib were confirmed in patients unresponsive to dupilumab, who were not included in upadacitinib trials.

Keyphrases

atopic dermatitis
end stage renal disease
ejection fraction
randomized controlled trial
newly diagnosed
chronic kidney disease
systematic review
peritoneal dialysis
high intensity